Episode Summary

Midlife heart health is not about panic — it’s about calibration.

In this American Heart Month solo episode, Rosemarie Beltz — cardiovascular perfusionist with nearly 30 years of clinical experience — breaks down what actually happens to cardiovascular risk during menopause, why “normal” fatigue may be measurable, and how high-functioning midlifers can recalibrate before a crisis.

This episode explores:

• The connection between menopause and heart disease
• Why arterial stiffness accelerates during the menopausal transition
• Coronary microvascular disease and why “normal tests” don’t always mean no problem
• Why heart disease remains the leading cause of death globally
• The importance of a midlife heart health checkup
• GLP-1 medications and evolving cardiometabolic science
• Why high performers need better data — not less care

If you are navigating midlife, perimenopause, menopause, stress, sleep shifts, or unexplained fatigue — this episode offers clarity, not fear.

This conversation builds on Rosemarie’s earlier interview with interventional cardiologist Dr. Kimberly Skelding on menopause and cardiovascular risk — part of Second Opinion’s longitudinal approach to midlife health.

Who This Episode Is For

• Women 40+ navigating perimenopause or menopause
• Midlife men avoiding preventive care
• High-functioning professionals who postpone their own labs
• Global listeners seeking evidence-based clarity
• Anyone who has been told “your tests are normal” but still feels off

Key Takeaways

• Midlife is not when heart disease starts — it’s when accumulation becomes measurable.
• Menopause is a vascular inflection point, not a moral failure.
• Coronary microvascular disease is more common in women, especially in low-estrogen states.
• A midlife heart checkup is calibration — not reassurance.
• GLP-1 medications are evolving cardiometabolic medicine, but fundamentals still matter.
• High performers require precision data, not dismissal.

Research & Clinical Sources Referenced

• CDC — Heart Disease Facts and Statistics
• CDC — American Heart Month Toolkit
• American Heart Association — Coronary Microvascular Disease
• SWAN Study (Study of Women’s Health Across the Nation) — Arterial stiffness and menopause transition
• FDA — Wegovy (semaglutide) cardiovascular risk reduction approval
• AHA Journals — Vascular aging in menopause

Related Episodes

If this episode resonated, continue here:

• Menopause & Heart Health: A Clinical Conversation with Dr. Kimberly Skelding
A foundational discussion on vascular risk, symptoms often dismissed in women, and precision cardiology in midlife.

• Midlife Fitness: Train Smarter, Not Harder
Strength training, hormones, and cardiometabolic health after 40.

• Sleep & the Midlife Nervous System
How sleep fragmentation drives hypertension and metabolic risk.

Second Opinion builds conversations longitudinally — not episodically.

Global Listener Note

Cardiovascular disease remains the leading cause of death worldwide.

To listeners across Canada, the UK, Ireland, Australia, Europe, Africa, and Asia — midlife vascular shifts are not regional. They are physiological.

Midlife women everywhere deserve better data.

If this episode was valuable:

• Follow or subscribe to Second Opinion
• Leave a review
• Share this episode with someone navigating midlife fatigue or stress
• Book your midlife heart health checkup

About Second Opinion

Second Opinion is hosted by Rosemarie Beltz — cardiovascular perfusionist, medical journalist, and midlife health authority.
Where science meets story.
Where age is always your advantage.

Produced from New York City.

🔗 Follow & Subscribe to never miss an episode. If you love the show, leave a review—it helps others get a second opinion!

💡 Have a topic you’d love for us to cover? Reach out at www.rosemarieb.com.